Sequential brief chemo-immunotherapy FND plus rituximab in elderly patients with advanced stage follicular lymphoma (FL): High clinical and molecular remission rate associated with a prolonged failure-free survival.

被引：0
|
作者：
Vitolo, U
Boccomini, C
Ladetto, M
Pogliani, E
Scalabrini, DR
Tarella, C
Castellino, C
Aglietta, M
Atolfi, M
Carpaneto, A
Corradini, P
Darbesio, A
De Crescenzo, A
Levis, A
Liberati, AM
Morandi, S
Orsucci, L
Pregno, P
Rigacci, L
Rossini, F
Tonso, A
Gallo, E
机构：
[1] ASO S Giovanni Battista, Turin, Italy
[2] Univ Turin, Turin, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1320
引用
收藏
页码：371A / 372A
页数：2
相关论文
共 9 条
  • [1] A brief course of chemo-immunotherapy FND plus rituximab is effective to induce a high clinical and molecular response in elderly patients with advanced stage follicular lymphoma (FL) at diagnosis.
    Vitolo, U
    Boccomini, C
    Ladetto, M
    Pogliani, E
    Scalabrini, DR
    Tarella, C
    Castellino, C
    Aglietta, M
    Astolfi, M
    Botto, B
    Carpaneto, A
    Corradini, P
    Darbesio, A
    De Crescenzo, A
    Levis, A
    Liberati, AM
    Morandi, S
    Orsucci, L
    Rigacci, L
    Rossini, F
    Tonso, A
    Gallo, E
    BLOOD, 2003, 102 (11) : 400A - 400A
  • [2] High clinical and molecular response rate in elderly patients with advanced stage follicular lymhoma treated at diagnosis with a brief chemo-immunotherapy FND plus Rituximab.
    Vitolo, U
    Boccomini, C
    Ladetto, M
    Rota-Scalabrini, D
    Pogliani, E
    Rigacci, L
    Carpaneto, A
    Liberati, AM
    Bertini, M
    Pregno, P
    Larizza, E
    Castellino, C
    Rossini, F
    Astolfi, M
    Botto, B
    Tonso, A
    Morandi, S
    Tarella, C
    Aglietta, M
    Gallo, E
    BLOOD, 2002, 100 (11) : 359A - 360A
  • [3] Front-line brief chemo-immunotherapy rituximab (R)-FND plus rituximab consolidation ± rituximab maintenance in elderly patients with untreated advanced stage follicular lymphoma (FL):: First interim analysis of a prospective randomized study (ML17638)
    Vitolo, Umberto
    Ladetto, Marco
    Gamba, Enrica
    Baldini, Luca
    Ceccarelli, Manuela
    Chiappella, Annalisa
    De Renzo, Amalia
    Di Raimondo, Francesco
    Gallamini, Andrea
    Guarini, Attilio
    Mantoan, Barbara
    Martelli, Maurizio
    Alvarez, Isabel
    Orsucci, Lorella
    Parvis, Guido
    Petrini, Mario
    Pinto, Antonello
    Pogliani, Enrico Maria
    Pozzi, Samantha
    Pulsoni, Alessandro
    Rigacci, Luigi
    Tucci, Alessandra
    Zaja, Francesco
    Gallo, Eugenio
    BLOOD, 2007, 110 (11) : 384A - 384A
  • [4] Elderly patients with untreated advanced stage follicular lymphoma (FL) treated with brief chemoimmunotherapy Rituximab® FND+/-rituximab maintenance:: Preliminary analysis of a prospective randomized study
    Vitolo, U.
    Ladetto, M.
    Boccomini, C.
    Gamba, E.
    Baldini, L.
    Ceccarelli, M.
    Chiappella, A.
    De Renzo, A.
    Di Raimondo, F.
    Gallamini, A.
    Mantoan, B.
    Martelli, M.
    Alvarez, I.
    Parvis, G.
    Petrini, M.
    Pinto, A.
    Pozzi, S.
    Pulsoni, A.
    Rigacci, L.
    Tucci, A.
    Zaja, F.
    Gallo, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 182 - 182
  • [5] Rituximab (R) Maintenance Versus Observation After Short Term Chemo-immunotherapy R-FND as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Updated Results and Safety of the Maintenance of An Intergruppo Italiano Linfomi (IIL) Randomized Trial.
    Vitolo, Umberto
    Boccomini, Carola
    Ladetto, Marco
    Gamba, Enrica
    Alvarez, Isabel
    Baldini, Luca
    Chiappella, Annalisa
    Chiarenza, Annalisa
    Corradini, Paolo
    De Renzo, Amalia
    Evangelista, Andrea
    Gallamini, Andrea
    Guarini, Attilio
    Hohaus, Stefan
    Liberati, Anna Marina
    Mantoan, Barbara
    Orsucci, Lorella
    Parvis, Guido
    Petrini, Mario
    Pinto, Antonello
    Pogliani, Enrico
    Pozzi, Samantha
    Pulsoni, Alessandro
    Rigacci, Luigi
    Russo, Eleonora
    Tarella, Corrado
    Tucci, Alessandra
    Zaja, Francesco
    Gallo, Eugenio
    BLOOD, 2009, 114 (22) : 680 - 680
  • [6] Front-Line Chemo-Immunotherapy Rituximab-FC plus Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Update of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)
    Baldini, Luca
    Pulsoni, Alessandro
    Rossi, Giuseppe
    Vitolo, Umberto
    Morra, Enrica
    Olivero, Barbara
    Cavalieri, Elena
    Merli, Francesco
    Rigacci, Luigi
    Nobile, Francesco
    Ferrario, Andrea
    Orsucci, Lorella
    Brugiatelli, Maura
    Musto, Pellegrino
    Deliliers, Giorgio Lambertenghi
    Gamba, Enrica
    BLOOD, 2009, 114 (22) : 1051 - 1051
  • [7] Front-Line Chemo-Immunotherapy Rituximab-FC plus Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324)
    Baldini, Luca
    Pulsoni, Alessandro
    Rossi, Giuseppe
    Vitolo, Umberto
    Morra, Enrica
    Olivero, Barbara
    Cavalieri, Elena
    Merli, Francesco
    Rigacci, Luigi
    Nobile, Francesco
    Orsucci, Lorella
    Brugiatelli, Maura
    Musto, Pellegrino
    Deliliers, Giorgio Lambertenghi
    Gamba, Enrica
    BLOOD, 2008, 112 (11) : 701 - 701
  • [8] Autologous Transplantation (autoHCT) is Associated with Improved Overall Survival (OS) in Follicular Lymphoma (FL) Patients (Pts) Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis
    Casulo, Carla
    Friedberg, Jonathan W.
    Ahn, Kwang Woo
    DiGilio, Alyssa
    Sureda, Anna
    Fenske, Timothy S.
    Smith, Sonali M.
    Hamadani, Mehdi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S35 - S36
  • [9] Nordic mantle cell lymphoma (MCL) project: Prolonged follow-up of 86 patients treated with BEAM/BEAC plus PBSCT confirms that addition of high-dose ara-c and rituximab to CHOP induction plus in-vivo purging with rituximab increases clinical and molecular response rates, PCR-Neg. Grafts, failure-free, relapse-free and overall survival.
    Geisler, CH
    Elonen, E
    Kolstad, A
    Laurell, A
    Andersen, NS
    Pedersen, LB
    Jerkeman, M
    Nordstroem, M
    Lauritzen, GF
    Ralfkiaer, E
    Aakerman, M
    Sundstroem, C
    Langholm, R
    Karjalainen-Lindsberg, ML
    BLOOD, 2004, 104 (11) : 6A - 6A
1